Immuneering Corporation (IMRX)

NASDAQ: IMRX · IEX Real-Time Price · USD
1.490
+0.060 (4.20%)
At close: Jun 24, 2024, 4:00 PM
1.470
-0.020 (-1.34%)
After-hours: Jun 24, 2024, 5:41 PM EDT
4.20%
Market Cap 44.18M
Revenue (ttm) n/a
Net Income (ttm) -54.18M
Shares Out 29.65M
EPS (ttm) -1.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 132,529
Open 1.430
Previous Close 1.430
Day's Range 1.430 - 1.550
52-Week Range 1.300 - 11.060
Beta -0.60
Analysts Buy
Price Target 15.14 (+916.11%)
Earnings Date Aug 1, 2024

About IMRX

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridg... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2021
Employees 65
Stock Exchange NASDAQ
Ticker Symbol IMRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for IMRX stock is "Buy." The 12-month stock price forecast is $15.14, which is an increase of 916.11% from the latest price.

Price Target
$15.14
(916.11% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Immuneering to Present at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad ...

26 days ago - GlobeNewsWire

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

- Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Tri...

6 weeks ago - GlobeNewsWire

Immuneering Recognizes Melanoma Awareness Month

- Two clinical stage product candidates in development for the treatment of melanoma - - RAS mutant melanoma represents one of five arms in the company's ongoing Phase 2a clinical study of IMM-1-104 -...

7 weeks ago - GlobeNewsWire

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibit...

2 months ago - GlobeNewsWire

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broa...

2 months ago - GlobeNewsWire

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

- Deep Cyclic Inhibitor of the MAPK pathway demonstrated strong tumor growth inhibition in preclinical studies of RAF or RAS mutant tumors, both as monotherapy and in combination - - Phase 1 portion o...

3 months ago - GlobeNewsWire

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for ct...

3 months ago - GlobeNewsWire

Immuneering Appoints Thomas J. Schall, Ph.D.

CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broa...

3 months ago - GlobeNewsWire

Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors

- First patient dosed with IMM-1-104 in combination with modified gemcitabine plus nab-paclitaxel for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) -

3 months ago - GlobeNewsWire

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - March 6, 2024) - Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on devel...

Other symbols: BLRXCADLONCY
3 months ago - Newsfile Corp

Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broa...

3 months ago - GlobeNewsWire

Immuneering to Participate in the Cowen 44th Annual Health Care Conference

CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broa...

4 months ago - GlobeNewsWire

Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

- Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 - - Dosing of first patient in the expanded Phase 2a portion of Phase 1/2a trial of IMM-1-104 expected i...

4 months ago - GlobeNewsWire

Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

– Fast Track designation has the potential to accelerate lead asset IMM-1-104's path to U.S. FDA submission for pancreatic ductal adenocarcinoma –

4 months ago - GlobeNewsWire

Immuneering Announces Participation in February Investor Conferences

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of ca...

5 months ago - GlobeNewsWire

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

- Dosing of first patient in the Phase 1/2a clinical trial expected in early 2024 - CAMBRIDGE, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncolog...

6 months ago - GlobeNewsWire

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients with...

7 months ago - GlobeNewsWire

Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates

-Dose evaluation portion of IMM-1-104 Phase 1/2a trial approximately two-thirds enrolled; Immuneering's recommendation for a Phase 2 dose expected in early 2024 -

8 months ago - GlobeNewsWire

Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven tumo...

9 months ago - GlobeNewsWire

Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an init...

9 months ago - GlobeNewsWire

Immuneering to Present at the Morgan Stanley Healthcare Conference

CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an ini...

10 months ago - GlobeNewsWire

Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates

- Positive initial pharmacokinetic, pharmacodynamic and safety data presented at American Association for Cancer Research (AACR) annual meeting, with IMM-1-104 demonstrating Cmax, half-life, and pERK/...

11 months ago - GlobeNewsWire

Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors

- No dose limiting toxicities observed with IMM-1-104 up to 320 mg once daily during the Phase 1a dose escalation portion of ongoing clinical study -

1 year ago - GlobeNewsWire

Immuneering to Present at the Jefferies Healthcare Conference

CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initi...

1 year ago - GlobeNewsWire

Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

- Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program presented at American Association for Cancer Research (AACR) annual meeting -

1 year ago - GlobeNewsWire